Inhibition of pathogenic agents including α6 1 integrin receptor or α6 4 integrin receptor at a surface

Disclosed are treatment agents and methods of treatment utilizing the agents directed toward diseases in which the disease causing pathogen includes α6 1 integrin receptors and/or α6 4 integrin receptors on the surface of the pathogen. In one embodiment, the disease can be breast cancer. The therape...

Full description

Saved in:
Bibliographic Details
Main Authors BORICK HEATHER P, BODINE ASHBY B, MARCOTTE, JR. WILLIAM R, SCOTT THOMAS R, SWIRE-CLARK GINGER A
Format Patent
LanguageEnglish
Published 23.11.2010
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:Disclosed are treatment agents and methods of treatment utilizing the agents directed toward diseases in which the disease causing pathogen includes α6 1 integrin receptors and/or α6 4 integrin receptors on the surface of the pathogen. In one embodiment, the disease can be breast cancer. The therapeutic agents disclosed include a polypeptide comprising at least a portion of the G domain of the laminin-5 α3 chain that has been shown to bind α6 1 integrin receptors and α6 4 integrin receptors. In one embodiment, the therapeutic agents can be fused or chimeric materials in which the laminin-5 α3 chain polypeptide has been chemically bound to another material that can be useful in the destruction or neutralization of the pathogen.
Bibliography:Application Number: US20060440746